DEF 14A: TransCode Therapeutics Seeks Stockholder Approval for Warrant Issuance and Potential Adjournment

TransCode Therapeutics is holding a special meeting to seek stockholder approval for the issuance of shares upon exercise of warrants and to potentially adjourn the meeting if necessary to solicit additional votes.

Summary

• TransCode Therapeutics is seeking stockholder approval for the issuance of common stock upon the exercise of Series C and Series D warrants to comply with Nasdaq Listing Rule 5635(d).
• The company also seeks approval for adjustments to the exercise price of the warrants, an increase in the underlying common stock, an alternative cashless exercise feature in the Series D warrants, and potential adjustments to the warrants upon the Shareholder Approval Date, subject to a floor price of $2.4882.
• A special meeting of stockholders is scheduled for February 4, 2025, to vote on these proposals.
• The board of directors unanimously recommends voting FOR both the Issuance Proposal and the Adjournment Proposal.
• The company completed a private placement on December 2, 2024, raising approximately $8 million before fees and expenses.
• The net proceeds from the private placement are intended for working capital and general corporate purposes.
• Holders of 173,033 shares of Common Stock issued pursuant to the Securities Purchase Agreement, dated November 26, 2024, will not be entitled to vote such stock.
• As a result, a total of 523,216 shares of Common Stock are entitled to vote on Proposal 1 and Proposal 2.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the need for stockholder approval for a previously completed private placement. While the capital raise is a positive, the potential dilution from warrant exercises introduces a degree of uncertainty.

Positives

• The private placement closed on December 2, 2024, providing the company with approximately $8 million in gross proceeds for working capital and general corporate purposes.
• The Board of Directors unanimously recommends that stockholders vote FOR approval of the Issuance Proposal and the Adjournment Proposal.

Negatives

• If the Issuance Proposal is not approved, the company will be required to hold a meeting every four months to seek Shareholder Approval until the earlier of the date on which Shareholder Approval is obtained or the date on which the Warrants are no longer outstanding.
• The time and expense of organizing and conducting stockholder meetings is not insignificant and the requirement to do so would be added expense, would distract management from operating the business, and may make raising additional capital in the future more difficult.

Risks

• Exercise of the warrants, including their reset, anti-dilution features, and alternative cashless exchange feature may result in substantial dilution to holders and purchasers of our Common Stock which may adversely affect the market price of our Common Stock.
• The reset feature in the warrants may adjust the exercise price downward and increase the number of shares issuable upon exercise under certain conditions thereby causing further dilution to existing stockholders.
• The potential for increased dilution due to the reset feature may exert downward pressure on the market price of our common stock.
• The issuance of additional shares upon exercise of the warrants with reset features could also make it more difficult for us to raise additional capital through future offerings of equity securities.
• Purchasers of our common stock may experience immediate and substantial dilution in the net tangible book value per share of their investment upon the exercise of these warrants, especially if the reset features are triggered and result in issuances of additional shares.

Future Outlook

The company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. If stockholder approval is not obtained, the company is obligated to hold a meeting every four months thereafter to seek Shareholder Approval until the earlier of the date on which Shareholder Approval is obtained or the date on which the Warrants are no longer outstanding.

Management Comments

• The Board of Directors unanimously recommends that stockholders vote FOR each of Proposal 1 and Proposal 2.

Industry Context

This type of request for shareholder approval is common for companies listed on the Nasdaq when issuing a significant number of shares or warrants that could result in substantial dilution, ensuring compliance with listing rules.

Comparison to Industry Standards

• The terms of the warrants, including the reset feature and cashless exercise option, are relatively common in private placements for small-cap biotech companies seeking to raise capital.
• The potential dilution impact needs to be carefully considered by investors, as it can affect the stock price and future fundraising ability, similar to other companies employing such financing strategies.

Stakeholder Impact

• Approval of the Issuance Proposal will allow the company to comply with Nasdaq listing rules and potentially access additional capital through warrant exercises.
• Existing stockholders may experience dilution if the warrants are exercised.
• Failure to approve the Issuance Proposal could lead to additional expenses and management distraction due to repeated stockholder meetings.

Next Steps

• Stockholders to vote on the Issuance Proposal and the Adjournment Proposal at the Special Meeting on February 4, 2025.
• The company will file a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to announce the final voting results.

Key Dates

Keywords

warrants, issuance, stockholder approval, Nasdaq Listing Rule 5635(d), private placement, common stock, dilution, exercise price, TransCode Therapeutics